替米沙坦对原发性高血压合并高脂血症患者血液流变学、血脂及血小板聚集功能的影响  

Effects of telmisartan on hemodynamics,blood lipids and the function of platelet aggregation in essential hypertensive patients with hyperlipidemia

作　　者：黄汉辉[1] 郑师明[1] 梅峥嵘[1] 严鹏科[1] 

机构地区：[1]广州医学院第三附属医院药剂科,广东广州510150

出　　处：《中国医院药学杂志》2011年第22期1883-1885,共3页Chinese Journal of Hospital Pharmacy

摘　　要：目的:研究原发性高血压合并高脂血症患者血液流变学、血脂和血小板聚集功能以及替米沙坦对其影响。方法:测定67例原发性高血压合并高脂血症受试者服用替米沙坦80 mg.d-1治疗8周前后血压、血液流变学参数、血脂及血小板聚集功能的变化。结果:使用替米沙坦治疗后,原发性高血压受试者总体血压水平(P<0.05)达到降压治疗的目的;能不同程度地降低受试者血液流变学、血脂和血小板聚集功能相关参数水平(P<0.05)。结论:替米沙坦能控制原发性高血压并改善血脂和血液黏度。OBJECTIVE To determine hemodynamics, blood lipids and the function of platelet aggregation in essential hypertensive patients with hyperlipidemia, and the effects of telmisartan on these items. METHODS Sixty-seven essential hypertensive patients with hyperlipidemia were treated with telmisartan 80 mg·d^-1 for 8 weeks. The blood pressure, hemodynamics, blood lipids and the function of platelet aggregation were investigated before and after telmisartan treatment. RESULTS Overall blood pressure levels in patients with essential hypertension were achieved antihypertensive treatment goal（P〈0. 05）. Relevant items of hemodynamics, blood lipids and the function of platelet aggregation were reduced simultaneously（P〈0. 05）. CONCLUSION Telmisartan can control and reduce blood lipids and blood viscosity in essential hypertensive patients with hyperlipidemia.

关 键 词：替米沙坦 原发性高血压 高脂血症 

分 类 号：R972.4[医药卫生—药品]